187
Views
0
CrossRef citations to date
0
Altmetric
Letters

No preventive or therapeutic efficacy of infliximab against macrophage activation syndrome due to systemic juvenile idiopathic arthritis

, , , , , & show all
Pages 246-248 | Accepted 24 Jun 2018, Published online: 08 Nov 2018
 

Acknowledgement

We thank Simon Teteris from the Edanz Group for editing the English text of a draft of this manuscript.

Disclosure statement

SI received grants and a lecture fee from Teijin Pharma Co. Ltd, Nihon Pharma Co. Ltd, Japan Blood Bank Organization, and Chugai Pharmaceutical Co. Ltd. None of the other authors declared any conflicts of interest.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 171.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.